PopVax's open-source COVID-19 vaccine PVX-001 enters first human trial
PVX-001: open-source Covid-19 vaccine starts Phase 1 trial
PopVax has dosed the first participants in a Phase I trial of PVX-001, an open-source, broadly protective COVID-19 vaccine. Built on an mRNA-encoded virus-like particle platform, it elicited over 50 times more neutralizing antibodies in mice than the same mRNA alone and remains stable at refrigerator temperatures for at least nine months. After the trial, PopVax will release the design and manufacturing know-how and will not enforce its patents against anyone making betacoronavirus vaccines.
Once the Phase I trial of PVX-001 concludes, we will open-source the design and manufacturing information needed for others to produce and build on it, and we will not enforce any of our intellectual property rights against anyone who uses it to make vaccines against any betacoronavirus.